Compare Torrent Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ABBOTT INDIA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ABBOTT INDIA TORRENT PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 37.0 51.9 71.3% View Chart
P/BV x 9.4 16.8 55.9% View Chart
Dividend Yield % 0.6 0.4 158.5%  

Financials

 TORRENT PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
ABBOTT INDIA
Mar-19
TORRENT PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,9648,834 22.2%   
Low Rs1,2455,458 22.8%   
Sales per share (Unadj.) Rs453.41,731.1 26.2%  
Earnings per share (Unadj.) Rs25.8211.9 12.2%  
Cash flow per share (Unadj.) Rs62.3219.9 28.3%  
Dividends per share (Unadj.) Rs17.0065.00 26.2%  
Dividend yield (eoy) %1.10.9 116.5%  
Book value per share (Unadj.) Rs279.2945.2 29.5%  
Shares outstanding (eoy) m169.2221.25 796.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.54.1 85.7%   
Avg P/E ratio x62.233.7 184.6%  
P/CF ratio (eoy) x25.832.5 79.3%  
Price / Book Value ratio x5.77.6 76.0%  
Dividend payout %65.930.7 215.0%   
Avg Mkt Cap Rs m271,513151,848 178.8%   
No. of employees `00013.63.5 390.2%   
Total wages/salary Rs m14,0384,356 322.3%   
Avg. sales/employee Rs Th5,642.610,555.5 53.5%   
Avg. wages/employee Rs Th1,032.41,249.9 82.6%   
Avg. net profit/employee Rs Th320.91,292.2 24.8%   
INCOME DATA
Net Sales Rs m76,72836,786 208.6%  
Other income Rs m5711,133 50.4%   
Total revenues Rs m77,29937,919 203.9%   
Gross profit Rs m19,8316,047 327.9%  
Depreciation Rs m6,177169 3,650.7%   
Interest Rs m5,03823 22,388.9%   
Profit before tax Rs m9,1876,989 131.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2542,485 50.4%   
Profit after tax Rs m4,3634,503 96.9%  
Gross profit margin %25.816.4 157.2%  
Effective tax rate %13.635.6 38.4%   
Net profit margin %5.712.2 46.5%  
BALANCE SHEET DATA
Current assets Rs m50,37527,610 182.5%   
Current liabilities Rs m51,6538,569 602.8%   
Net working cap to sales %-1.751.8 -3.2%  
Current ratio x1.03.2 30.3%  
Inventory Days Days9260 152.9%  
Debtors Days Days6827 249.3%  
Net fixed assets Rs m83,6481,057 7,914.6%   
Share capital Rs m846213 398.2%   
"Free" reserves Rs m46,39719,873 233.5%   
Net worth Rs m47,24420,086 235.2%   
Long term debt Rs m39,1290-   
Total assets Rs m141,20929,409 480.2%  
Interest coverage x2.8311.6 0.9%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.51.3 43.4%   
Return on assets %6.715.4 43.3%  
Return on equity %9.222.4 41.2%  
Return on capital %12.334.9 35.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,103369 5,990.5%   
Fx outflow Rs m5,5224,918 112.3%   
Net fx Rs m16,581-4,549 -364.5%   
CASH FLOW
From Operations Rs m17,9814,991 360.2%  
From Investments Rs m-2,413-2,570 93.9%  
From Financial Activity Rs m-13,145-1,428 920.5%  
Net Cashflow Rs m2,380993 239.6%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 7.9 88.9%  
FIIs % 12.6 0.1 12,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.1 51.5%  
Shareholders   26,511 18,270 145.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  FRESENIUS KABI ONCO.  DR. REDDYS LAB  GSK PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - LUPIN COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS